Room: Stars at Night Ballroom 1
Purpose: The Halcyonâ„¢ system is Varianâ€™s newest cancer treatment device, engineered to simplify aspects of image-guided volumetric intensity-modulated radiotherapy (IMRT). Due in part to its simplicity, low and middle income countries (LIMCs) or other resource limited environments may stand to benefit from this technology. The purpose of this work is to develop a simple modern commissioning and on-going QA strategy for LIMCs that can be used for rapid and safe adoption of the Halcyon.
Methods: An international group of collaborators (Australia and U.S.) developed a simplified commissioning strategy. Design constraints required that the commissioning was focused on a small set of end-to-end tests with specified equipment and that users must be able to compare their commissioning data. The AAPM Task Group 119 was used as the basis for end-to-end test creation. A web-based data repository was designed for all participating centers to upload their point-dose measurements.
Conclusion: The process of end-to-end tests will verify the entire treatment chain including the ability of the user to CT scan a phantom, create contours, and perform treatment planning using Eclipse. Data from the Eclipse treatment plans are compared to all the other Halcyon users in the system.
Funding Support, Disclosures, and Conflict of Interest: The measurement equipment used in this work was supported by a grant from Varian Medical Systems.